Novartis muscle wasting drug gets 'breakthrough' status
ZURICH (Reuters) - Novartis said on Thursday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM). (Source: Reuters: Health)
Source: Reuters: Health - August 20, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Ultragenyx reports positive interim data from Phase II study of oral sialic acid tablet
Clinical-stage biotechnology company Ultragenyx Pharmaceutical has reported positive interim data from Phase II study of an oral sialic acid extended-release (SA-ER) tablet, UX001, in hereditary inclusion body myopathy (HIBM). (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2013 Category: Pharmaceuticals Source Type: news
Single Mutations In VCP Gene Implicated In A Number Of Neurodegenerative Diseases
This study shows that these mutations disrupt energy production in cells shedding new light on the role of VCP in these multiple disorders... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Mutations in VCP gene implicated in a number of neurodegenerative diseases
(University College London) New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget's Disease of the Bone and Frontotemporal Dementia, and the motor neuron disease Amyotrophic Lateral Sclerosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2013 Category: Global & Universal Source Type: news
